Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2007

View Archived Issues

Novel therapeutic agents for cancer covered in recent patents

Recent Merck & Co. and Actelion patents disclose new immunomodulatory agents

New agents for substance abuse imparted in recent Auspex patent

Snapshots of clinical trial data presented at EULAR 2007

Patient enrollment complete in phase III telavancin study

Lorus initiates GTI-2040 clinical trial in acute leukemia and MDS

Alexza Pharmaceuticals seeks to expand AZ-104 indication

Methotrexate prodrug effective in experimental models of rheumatoid arthritis

SLx-2119: a potent ROCK-2 inhibitor that inhibits septic liver injury in vivo

MIF inhibition shows promise in murine models of arthritis

LEO Pharma's novel p38 MAPK inhibitor shows efficacy in animal models of arthritis and psoriasis

Successful follow-up study of QR-443 in cachexia model

Gardasil sBLA accepted for review

RAID program supports development of SR-16388 to treat advanced cancers

Inspire and FAES Farma amend oral bilastine licensing agreement

HuCAL-derived antibody to begin phase I in oncology

End of phase II meeting for Qnexa

IND filing for Src kinase inhibitor KX2-391

Date set for Advisory Committee review of Repel-CV PMA

Phase II trial planned for LCP-Tacro in prevention of organ rejection

DSMB recommendation to continue European tramiprosate phase III study

Antiviral response observed in bevirimat 250 mg cohort

Dextofisopam advances to phase IIb IBS study

Anadys Pharmaceuticals nominates ANA-598 for clinical development

FDA approves commencement of phase II iclaprim trial

E.U. approval for Soliris

Rasilez recommended for E.U. approval

Lyrica approved for fibromyalgia

E.U. approval recommended for Atriance in relapsed or refractory T-ALL, T-LBL

FDA approves sugar-free Carnitor for carnitine deficiency

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...